Carlo Tanzi Phd Email Address

Principal and Founder

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. A Phase 2 study of Seres' program SER-109 has been completed in multiply recurrent Clostridium difficile infection. Seres' clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI.

Biotech investor relations consultant. Founded Kendall Investor Relations to provide strategic and operational IR services to publicly traded and private biotech companies. I am a results oriented biotechnology professional with wide ranging expertise including: investor relations and corporate communications, clinical development, product strategy, commercialization, finance, and valuation. Track record effectively leading program teams for two extremely successful marketed products, (Tecfidera and Tysabri) during periods of development and commercialization. Investor relations officer providing expert communication guidance to senior management at both large and smaller companies. Communication background includes multiple high profile Phase 2 and Phase 3 clinical data read-outs, four product launches, and management of numerous corporate earning releases, conference calls, and R&D investor days. Established, deep relationships with investors, and sell-side analysts. Ph.D. in cell and molecular biology with a focus on virology.